Recent searches
Search options
Administered by:
Phase 1 clinical study in 232 multiple myeloma patients who received Talquetamab (a bispecific antibody against CD3 and GPRC5D, redirects T cells to mediate killing of GPRC5D-expressing myeloma cells) showed:
New England Journal of MedicineTalquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma | NEJMOriginal Article from The New England Journal of Medicine — Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
-side-effects of CRS (80%), skin changes (70%), and dysgeusia (63%) of patients
-median follow-ups of 11.7 months (at the 405-μg dose level) and 4.2 months (at the 800-μg dose level).
-ORR 70% (at the 405-μg dose level) and 64% (at the 800-μg dose level).
-median duration of response was 10.2 months (at the 405-μg dose level) & 7.8 months (at the 800-μg dose level).